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Reduced P53 levels ameliorate
neuromuscular junction loss without
affecting motor neuron pathology in a
mouse model of spinal muscular atrophy
Natalie L. Courtney1,2, Alannah J. Mole1,2, Alison K. Thomson1,2 and Lyndsay M. Murray1,2
Abstract
Spinal Muscular Atrophy (SMA) is a childhood motor neuron disease caused by mutations or deletions within the
SMN1 gene. At endstages of disease there is profound loss of motor neurons, loss of axons within ventral roots and
defects at the neuromuscular junctions (NMJ), as evidenced by pathological features such as pre-synaptic loss and
swelling and post-synaptic shrinkage. Although these motor unit defects have been widely described, the time course
and interdependancy of these aspects of motor unit degeneration are unclear. Recent reports have also revealed an
early upregulation of transcripts associated with the P53 signalling pathway. The relationship between the
upregulation of these transcripts and pathology within the motor unit is also unclear. In this study, we exploit the
prolonged disease timecourse and deﬁned pre-symptomatic period in the Smn2B/− mouse model to perform a
temporal analysis of the different elements of motor unit pathology. We demonstrate that NMJ loss occurs prior to cell
body loss, and coincides with the onset of symptoms. The onset of NMJ pathology also coincides with an increase in
P53-related transcripts at the cell body. Finally, using a tamoxifen inducible P53 knockout, we demonstrate that post-
natal reduction in P53 levels can reduce NMJ loss, but does not affect other aspects of NMJ pathology, motor neuron
loss or the phenotype of the Smn2B/− mouse model. Together this work provides a detailed temporal description of
pathology within motor units of an SMA mouse model, and demonstrates that NMJ loss is a P53-dependant process.
This work supports the role for P53 as an effector of synaptic and axonal degeneration in a die-back neuropathy.
Introduction
Spinal Muscular Atrophy (SMA) is a childhood form of
motor neuron disease that is caused by homozygous loss
of the SMN1 gene1,2. The most common form of this
disease has an onset of less than 6 months of age and a life
expectancy of under 2 years without signiﬁcant respira-
tory support.
The classic morphological features of motor unit
pathology in SMA have been extensively characterised
and widely used to assess outcome in pre-clinical testing3.
They include a loss and cytoplasmic shrinkage of motor
neuron cell bodies, loss of axons in the ventral roots and
pathology at the neuromuscular junctions (NMJ),
including denervation, pre-synaptic accumulation of
neuroﬁlaments, endplate abnormalities, and muscle ﬁbre
atrophy4,5. Such defects have been consistently observed
in both patients and animal models of SMA at sympto-
matic stages of disease. How these pathologies throughout
the motor unit are temporally related to each other, and
to the onset of symptoms, is currently less clear.
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It is thought that motor neurons degenerate in a ‘die-
back’ manner, as the pre-synaptic terminal appears to
withdraw from the post-synaptic endplate, leaving par-
tially occupied endplates6. Furthermore, ventral root axon
loss appears to be more severe than motor neuron cell
body loss, which is indicative of distal to proximal
degeneration of the motor neuron7. NMJ defects occur
prior to symptom onset in mouse models of SMA sug-
gesting that the NMJ is an ‘early pathological target’ in
SMA6,8. However, the temporal and causative relationship
of NMJ degeneration to the loss of motor neuron cell
bodies is unknown.
It may be suggested that the observed defects at the
NMJ in SMA mosue models are reﬂective of a require-
ment for Smn in the axon or synapse. However it is
currently unclear whether synaptic pathology is a cause or
effect of motor neuron death, and it remains possible that
synaptic and axonal pathology observed are morphlogical
evidence of cell death, as the motor neuron retracts its
most distal processes. This idea is supported by the
osbervation that there is an increase in transcripts asso-
ciated with the P53 signalling pathway in motor neuron
cell bodies at pre-symptomatic time points in SMA mouse
models8. As this upregulation is more prominent in
selectively vulnerable motor neurons, P53 may play a role
in the breakdown of the motor unit8,9.
P53 plays a crucial role in co-ordinating the cellular
response to stress. Initially characterised as a transcription
factor, more recent work indicates it can also act as a
translational regulator and interact with regulatory
RNAs10–12. P53 is activated in response to a variety of
cues including cell stress and DNA damage, and directs
cellular responses, including senescence, DNA repair and
apoptosis13. Although best characterised as a tumour
suppressor, P53 has also been strongly implicated in a
range of neurodegenerative disorders, including the adult
onset motor neuron disease amyotrophic lateral sclerosis
(ALS)14–19. An increase in P53 has been reported in
postmortem patient spinal cord20 and an increase in
transcripts associated with the P53 signalling pathway
have been widely reported in motor neurons and spinal
cord tissue from SMA model mice8,21–24.
The cause and consequence of P53 upregulation in
SMA motor neurons is currently unclear. Given its well-
established involvement in pro-apoptotic pathways, it is
tempting to speculate that this upregulation is reﬂective of
the onset of cell death pathways at the motor neuron.
However, a direct interaction between Smn and P53 has
also been observed, which was suggestive of an anti-
apoptotic role for Smn25. The increase in the
P53 signalling pathway may therefore be reﬂective of a
primary defect caused by reduced Smn levels. However,
since P53 activity appears restricted to selectively vul-
nerable motor neurons, it is also possible that P53 acts
downstream of Smn, in mediating the breakdown of
selectively vulnerable motor neuron pools. P53 has also
been shown to localise to the synapse where it plays a role
in mitochondrial dysfunction and oxidative stress fol-
lowing DNA damage26. P53 has also been shown to reg-
ulate a range of synaptic genes and that synaptic activity
can regulate P53 levels27,28. It is therefore unclear what, if
any, role P53 has in the onset and progression of motor
unit pathology in SMA.
Here, we use the Smn2B/− mouse model of SMA to
demonstrate that the onset of NMJ degeneration precedes
motor neuron cell body loss, thus conﬁrming that motor
neurons degenerate in a distal to proximal manner. We
demonstrate that the ﬁrst evidence of pre-synaptic swel-
ling at the NMJ coincides with an increase in P53 asso-
ciated transcripts in the spinal cord. In order to
investigate the causal effects of P53 pathway activation, we
have crossed the Smn2B/− mouse model with a mouse
carrying a tamoxifen inducible P53 knockout. Postnatal
knockout of P53 led to a reduction in NMJ loss, with no
beneﬁt observed upon any other features of NMJ
pathology, motor neuron loss or mouse phenotype. In
summary, we show that NMJ loss is a consequence of P53
pathway activation, and that partially preserving the
structure of the NMJ confers no beneﬁt to the overall
health of the motor neuron or mouse. P53 therefore
appears to play a role in the breakdown and degeneration
of synaptic connections, but does not appear to be central
to the motor unit pathology caused by depleted Smn
levels.
Results
NMJ pathology precedes motor neuron cell body loss in
the Smn2B/− mouse model
To investigate the correlation between NMJ and cell
body pathology, we have performed a detailed temporal
analysis of the NMJ and motor neuron cell body
throughout disease in the Smn2B/− mouse model of
SMA29. The aim of this work was to give insight into the
causal relationship between pathology in these distinct
parts of the motor neuron.
In our hands, the Smn2B/− mouse model displays a
signiﬁcant reduction in body weight from around P10,
and motor deﬁcits (as evidenced by an increase in the
time taken to self right) which are evident at around P9
(Supplementary Fig. 1). It has a life expectancy of around
20 days.
NMJ pathology was assessed in the transversus abdo-
minis muscle (TVA), a muscle which has demonstrated
signiﬁcant defects across all mouse models of SMA which
have been studied to date6,29,30. Consistent with previous
reports29, analysis of the TVA muscle at P15 revealed
signiﬁcant pre-synaptic pathology, as evidenced by a
decrease in the percentage of fully occupied endplates and
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signiﬁcant increase the percentage of NMJs displaying
mild, moderate or severe swelling (Fig. 1a–c). A time-
course analysis of these markers of pre-synaptic pathology
revealed that the earliest time point at which they could
be detected was at P10. This was the ﬁrst time point at
which denervation could be detected, as evidenced by a
small but signiﬁcant increase in the percentage of partially
occupied endplates. There was also a signiﬁcant increase
in the percentage of NMJs with mild or moderate pre-
synaptic swelling. There was a trend towards a decrease in
endplate size at P10, which was statistically signiﬁcant by
P15 (Fig. 1a–d). Overall, this data suggests that the onset
of NMJ pathology occurs after P5 but is present by P10.
As hindlimb weakness is a prominent feature of this
mouse model, we also analysed the tibialis anterior mus-
cle. At P10, there was no evidence of denervation
Fig. 1 The onset of NMJ pathology is between P5 and P10 in the Smn2B/− mouse model of SMA. a Representative confocal images showing
maximum intensity projection of confocal z-stack of NMJs in the TVA of Smn2B/− and Smn2B/+ mice at P1, P5, P10 and P15. Note that white
arrowheads show no pre-synaptic swelling, yellow arrowheads show mild pre-synaptic swelling while blue arrowheads show moderate pre-synaptic
swelling. Vacant endplates (red arrowhead) are seen at P15 in the Smn2B/− mouse model of SMA. The grayscale images show, from top to bottom,
BTX and NF/SV2. Scale bar= 20 μm. b Bar chart (mean ± SEM) compares the percentage of full, partial and vacant endplates in Smn2B/− mice
compared to Smn2B/+ controls. At P1 and P5, 100% of endplates in Smn2B/− and Smn2B/+ mice were fully occupied by the pre-synaptic terminal. At
P10, there is signiﬁcant increase in the percentage of partially occupied endplates and at P15, there is a signiﬁcant increase in the percentage of both
vacant and partially occupied endplates in Smn2B/− compared to Smn2B/+ mice (by Mann–Whitney-U test, *p < 0.05, **p < 0.01; n= 4 mice per
genotype). c Bar chart (mean ± SEM) compares the stages of pre-synaptic swelling in Smn2B/− and Smn2B/+ mice. There is no signiﬁcant difference in
the level of swelling in Smn2B/−mice compared to controls at P1 and P5. At P10, there is a signiﬁcant increase in the percentage of NMJs with stage 2
and stage 3 swelling in Smn2B/− mice. At P15, there is a signiﬁcant increase in the percentage of pre-synaptic terminals with stage 2, 3 and 4 swelling
in Smn2B/− mice compared to Smn2B/+ controls (by Mann–Whitney-U test, *p < 0.05; n= 4 mice per genotype). d The graph (mean ± SEM) compares
the average size of endplates in the TVA of Smn2B/− mice compared to controls. At P1 and P10 there is no signiﬁcant difference in the area of post
synaptic endplates in Smn2B/−mice compared to Smn2B/+ controls. At P5, there is a small but signiﬁcant increase in endplate area in Smn2B/−mice. At
P15 there is a signiﬁcant decrease in the size of endplates in Smn2B/−mice compared to controls (unpaired t-test, *p < 0.05, **p < 0.01; n= 4 mice per
genotype)
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(Supplementary Fig. 2). This conﬁrms that, although there
is evidence of NMJ swelling in the P10, it is not more
affected than the TVA muscle.
To investigate how pre-synaptic pathology is associated
with a loss of motor neuron cell bodies, we quantiﬁed the
number of motor neurons in the thoracic spinal cord. The
ﬁrst decrease in motor neuron cell body number could be
detected at P15, where a 48.4% decrease in motor neuron
number was observed (Fig. 2b). Prior to this time point,
there was no decrease in the number of motor neurons
and indeed, an intriguing trend towards an increase in the
number of motor neurons at P5, in the Smn2B/− model
compared to controls. There was also a signiﬁcant
decrease in motor neuron cell body area at P15, with no
observable difference at P10 or younger (Fig. 2c).
Together with the data above, this demonstrates that
NMJ pathology, which was ﬁrst observed at P10, precedes
motor neuron cell body shrinkage and loss, which was
ﬁrst observed at P15. This would suggest that motor
neuron pathology does indeed progress in a distal to
proximal manner, with NMJ loss preceding motor neuron
cell body loss.
NMJ pathology coincides with an increase in P53 related
transcripts at the cell body
The data above indicate that NMJ pathology starts
between P5 and P10. Previous work has shown that in this
mouse model, at P10 there is an increase in transcripts
associated with the P53 signalling pathway, including Fas,
Pmaip and Cdkn1a8. Given the known links between the
P53 signalling pathway and the onset of apoptosis, we
have previously hypothesised that the increase in these
transcripts was associated with the onset of motor neuron
cell death. As we have now also observed that NMJ
pathology ﬁrst appears around the same time, it is pos-
sible that NMJ pathology is a consequence of P53 pathway
activation at the cell body. We were therefore keen to
explore the temporal relationship between an increase in
transcripts associated with the P53 signalling pathway,
and the onset of NMJ pathology.
We ﬁrst aimed to further narrow down the time point at
which NMJ pathology could be ﬁrst seen. We therefore
analysed NMJs in the TVA muscle from P7 mice (Fig.
3a–c). This revealed no evidence of denervation, but a
signiﬁcant increase in NMJs with mild pre-synaptic
swelling. From this, we conclude denervation starts
between P7 and P10 and is preceded by pre-synaptic
swelling, which starts between P5 and P7.
Previous work has shown the transcripts Fas, Pmaip
and Cdkn1a are signiﬁcantly increased at P10 in this
mouse model8. We therefore analysed spinal cords at P5
and P7. This revealed no increase in transcripts at P5, but
a signiﬁcant increase in Fas and Pmaip at P7 (Fig. 3d, e).
Together this data shows a remarkable temporal
correlation between the onset of NMJ swelling and the
increase in transcripts associated with the P53 signalling
pathway.
Inhibition of the P53 signalling pathway reduces NMJ loss
without affecting phenotype of the Smn2B/− mouse model
Thus far we show that NMJ pathology precedes cell
body loss, but coincides with the increase in transcripts
associated with the P53 signalling pathway. To investigate
the relationship between P53 pathway activation and NMJ
pathology, we aimed to inhibit the P53 signalling pathway
by generating an inducible P53 knockout mouse on an
SMA model background. We generated this model by
introducing a P53 gene ﬂanked by loxP sites (P53ﬂ/ﬂ) as
well as cre-recombinase under the control of the oestro-
gen receptor promoter (CAG-Cre) onto the Smn2B/−
background. The resultant Smn2B/−; P53ﬂ/ﬂ; CAG-Cre
mice are equivalent to the original Smn2B/− mouse model,
however upon the administration of tamoxifen, the Cre-
recombinase causes the recombination of the P53 gene to
render it non-functional.
For these experiments we have four genotypes of mice:
Smn2B/+ control mice who have the P53ﬂ/ﬂ gene but do
not carry CAG-Cre (Smn2B/+; P53+/+); Smn2B/− mice who
have the P53ﬂ/ﬂ gene but do not carry CAG-Cre (Smn2B/−;
P53+/+); Smn2B/+control mice who have the P53ﬂ/ﬂ gene
and CAG-Cre (Smn2B/+; P53−/−); and Smn2B/− mice who
have the P53ﬂ/ﬂ gene and CAG-Cre (Smn2B/−; P53−/−)
(Fig. 4a). Upon administration of tamoxifen, the P53 gene
in only the latter two groups of mice will undergo
recombination and essentially be ‘knocked out’. Tamoxifen
(75mg/kg) was administered at P4 and P5. This time point
was selected as it was prior to any evidence of P53 pathway
activation in the spinal cord. Quantitative PCR results on
cDNA from spinal cord from P15 mice revealed P53 levels
were reduced by around 50% in both Smn2B/+; P53−/− and
Smn2B/−; P53−/− mice compared to their respective con-
trols (Fig. 4b).
To determine the effect of P53 knockout on the phe-
notype of the Smn2B/− mouse, weight and motor perfor-
mance were assessed daily following administration of
tamoxifen at P4 and P5. Knockout of P53 did not improve
the phenotype of Smn2B/− mice (Fig. 4c–e). Indeed, both
groups with reduced P53 levels displayed a small but
signiﬁcant decrease in body weight. There was a trend
towards poorer performance in the time to right test for
both Smn2B/− groups at P8, but there was no signiﬁcant
difference between Smn2B/−; P53+/+ and Smn2B/−; P53−/−
at either P8 or P10. Furthermore, in the ‘turn around’ test,
although Smn2B/−;P53−/− mice performed signiﬁcantly
worse at P13, 14 and 15 compared to Smn2B/+;
P53−/− controls, there was no signiﬁcant difference
between Smn2B/−; P53+/+ and Smn2B/−; P53−/−mice. This
data demonstrate that reduction of P53 confers no beneﬁt
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Fig. 2 Alterations in MNCB number and size occur between P10 and P15 in the Smn2B/− mouse model of SMA. a Representative images
showing MNCBs from Smn2B/− and Smn2B/+ control mice at P1, P5, P10 and P15. Note the comparable size difference between Smn2B/− and Smn2B/+
mice at P15. The grayscale images shown below each coloured image are the separate channels and show, from left to right, ChAT, Nissl and DAPI
staining. Scale bar= 20 µm. b The graph shows the absolute number of MNCBs counted in the ventral horn of the thoracic spinal cord of Smn2B/−
and control mice. At P1, P5 and P10 there is no signiﬁcant difference between Smn2B/− and Smn2B/+ pairs. At P15 there is a signiﬁcant decrease in the
number of MNCBs in Smn2B/−mice compared to Smn2B/+ controls (by unpaired student's t-test, *p < 0.05, n= 3 mice per genotype, per time point). c
The graph (mean ± SEM) shows that at P1, P5 and P10 there is no signiﬁcant difference in the average area of MNCBs in the ventral horn of the spinal
cord of Smn2B/− and Smn2B/+ mice. However, there is a signiﬁcant decrease in the average area of MNCBs in Smn2B/− mice compared to Smn2B/+
mice at P15 (by Unpaired t-test, ns > 0.05, *p < 0.05, n= 4 mice per genotype)
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Fig. 3 (See legend on next page.)
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to the motor performance of Smn2B/− mice, and if any-
thing, makes it worse.
We next assessed the impact of reduced P53 levels on
motor neuron cell body loss. Reduced P53 levels did not
affect motor neuron cell body loss or shrinkage. Quanti-
ﬁcation of the number of motor neurons in the
T4–T8 segments of the spinal cord at P15 revealed a loss
of 55.2 ± 9.6% and 52.0 ± 1.7% in Smn2B/−; P53+/+ and
Smn2B/−; P53−/− compared to their respective controls
(Fig. 5b). There was no signiﬁcant difference between
Smn2B/−; P53+/+and Smn2B/−; P53−/− mice. There was a
trend for motor neurons from Smn2B/−; P53+/+ and
Smn2B/−; P53−/− mice to be smaller compared to their
respective controls but again there was no signiﬁcant
difference between Smn2B/−; P53+/+ and Smn2B/−; P53−/−
mice (Fig. 5c). Overall, in the Smn2B/− mouse model,
reduced P53 levels do not appear to reduce motor neuron
cell body loss or shrinkage.
Finally, we assessed the effect of reduced P53 levels of
NMJ pathology. This revealed that reduced P53 levels
decreased NMJ loss (Fig. 6). Quantiﬁcation of the per-
centage of fully occupied endplates at P15 in Smn2B/−;
P53−/− mice revealed a signiﬁcant increase (Fig. 6b). This
was accompanied by a signiﬁcant decrease in the per-
centage of vacant endplates (Fig. 6c). Interestingly,
examination of pre-synaptic swelling, endplate matura-
tion and endplate area revealed no improvement in
Smn2B/−; P53−/− compared to Smn2B/−; P53+/+ (Fig.
6d–f). Together this data suggest that NMJ loss is a
consequence of P53 pathway activation, and dissociates
NMJ loss from other markers of pathology at the NMJ,
which are P53 independent.
Discussion
Here we have shown that pathology at the NMJ pre-
cedes loss or shrinkage of motor neurons at the level of
the cell body. A loss of NMJs was ﬁrst observed at P10,
whereas motor neuron loss was not observed until P15.
This ﬁrst evidence of NMJ swelling appears to coincide
with an increase in transcripts associated with the
P53 signalling pathway in the spinal cord. Importantly,
post-natal ‘knockout’ of P53 led to a reduction in NMJ
loss, without affecting other aspects of NMJ pathology,
motor neuron loss or affecting the phenotype of the
mouse. Together the work provides a detailed temporal
description of pathology within the motor units of an
SMA mouse model, and demonstrates that NMJ loss is a
P53-dependent process. This work supports the role for
P53 as an effector of synaptic and axonal degeneration in
a die-back neuropathy.
Temporal and mechanistic dissociation of motor unit
pathology in SMA
The protracted lifespan of the Smn2B/− mouse, com-
pared to the majority of other commonly used mouse
models, has allowed us to examine the evolution of dif-
ferent aspects of motor unit pathology, and revealed a
temporal dissociation between them. Motor neuron loss
and shrinkage is one of the last detectable morphological
abnormalities and evident only after symptom onset.
Swelling of the pre-synaptic terminal preceded NMJ loss
and post-synaptic changes, and also preceded the emer-
gence of symptoms. This is in agreement with studies on
the SOD1G93A mouse model of adult onset motor neuron
disease in which pre-synaptic defects were shown to
coincide with symptom onset, and motor neuron cell
body loss was observed as a late event31. Swelling
appeared to coincide with the earliest time point that
increased levels of Fas, and Pmaip can be detected. Given
the known links of these transcripts with the
P53 signalling pathway, this suggests that there is a cor-
relation between the onset of NMJ abnormalities and P53
pathway activation. Together this data suggest that, with
regards to motor unit pathology, the ﬁrst detectable
abnormality is swelling of NMJs, which coincides with
transcriptional changes at the cell body. This is then fol-
lowed by denervation, then by post-synaptic shrinkage
and loss and shrinkage of the motor neuron cell body.
The reduction in P53 levels allows us to more carefully
dissect the interdependency of these early events. Reduced
P53 levels had no effect on swelling, but did reduce
denervation. This shows that pre-synaptic swelling is a
(see ﬁgure on previous page)
Fig. 3 Activation of the P53 signalling pathway coincides with the onset of NMJ pathology. a Representative images of NMJs in the TVA of P7
Smn2B/− and Smn2B/+ mice. White arrowheads show stage 1 swelling and yellow arrowheads show stage 2 pre-synaptic swelling. Scale bar= 20 µm.
b Bar chart (mean ± SEM) shows that at P7, 100% of endplates in the TVA of Smn2B/− and Smn2B/+ mice were fully occupied by the pre-synaptic
terminal of an axon. (Mann–Whitney-U test, ns > 0.05; n= 4 mice per genotype). c Bar chart (mean ± SEM) compares the stages of pre-synaptic
swelling in Smn2B/− mice compared to Smn2B/+ controls. There is a signiﬁcant decrease in the percentage of pre-synaptic terminals with stage
1 swelling and increase in stage 2 swelling in the TVA of Smn2B/− mice compared to Smn2B/+ controls at P7. (Mann Whitney-U test, **p < 0.01; n= 4
mice per genotype). d The bar chart (mean ± SEM) shows that there is no signiﬁcant difference in the expression of transcripts involved in the
P53 signalling pathway in the thoracic spinal cord of Smn2B/− mice compared to Smn2B/+ mice at P5 (by Mann–Whitney-U test; ns > 0.05; n= 4 per
genotype). e The bar chart (mean ± SEM) shows that there is a signiﬁcant increase in the expression of transcripts involved in the P53 signalling
pathway, speciﬁcally in Cdkn1A and Pmaip1, in the thoracic spinal cord of Smn2B/− mice compared to Smn2B/+ mice at P7 (by Mann–Whitney-U test;
ns > 0.05; n= 4 per genotype)
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P53-independent event, whilst denervation is a P53-
dependant event. Thereby, whilst the pathology present at
the NMJ is not dependent upon the P53 pathway, the
actual process of pre-synaptic withdrawal is.
A role for P53 in mediating synaptic and axonal
degeneration
The data presented here demonstrate that knockout of
P53 can reduce NMJ loss, and therefore suggest that axon
Fig. 4 Reduction in P53 levels does not ameliorate the phenotype of the Smn2B/− mouse model. a Representative images of mice with the
various genotypes within experimental litters at P15. Scale bar= 1 cm. b Bar chart (mean ± SEM) shows that there is a signiﬁcant decrease in P53 at
the transcript level in the spinal cord of Smn2B/+; P53−/− mice compared to Smn2B/+; P53+/+ mice and in Smn2B/−; P53−/− mice compared to Smn2B/−;
P53+/+ mice (by Mann–Whitney-U test, *p < 0.05, **p < 0.001; n= 3 for Smn2B/−; P53+/+, n= 4 for all other genotypes). c The graph (mean ± SEM)
shows body weight in Smn2B/+; P53+/+ and Smn2B/+; P53−/− on the left and Smn2B/−; P53+/+ and Smn2B/−; P53−/− on the right. There is a signiﬁcant
reduction of weight in mice that are P53−/− in both Smn2B/+ and Smn2B/− groups, compared to P53+/+ mice. Two-way ANOVA with multiple
comparison *P < 0.05; *P < 0.001 (d, e) Graphs (mean ± SEM, with individual data points showing mean of three trials for individual animals) shows
performance in the time to right test (d) and the time to turn around test (e) for Smn2B/+; P53+/+, Smn2B/−; P53+/+, Smn2B/+; P53−/− and Smn2B/−;
P53−/− at P8 and P10 (d) and between P12 and P15 (e). In both tests, at all-time points, there is no signiﬁcant difference in motor performance
between Smn2B/−; P53−/− and Smn2B/−; P53+/+ mice. At P13, 14 and 15, Smn2B/−; P53−/− displayed a signiﬁcantly longer time to turn around than
Smn2B/+; P53−/− controls. (Kruskal Wallis with Dunn’s multiple comparison test; ns > 0.05, *p < 0.05, **p < 0.01, n= 5 for Smn2B/+; P53+/+ and Smn2B/−;
P53+/+; n= 4 for Smn2B/+; P53−/−; n= 3 for Smn2B/−; P53−/− for all time points except P15 where n= 4 for Smn2B/+; P53+/+ and Smn2B/+; P53−/−;
n= 6 for Smn2B/−; P53+/+ and n= 5 for Smn2B/−; P53−/−
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and synaptic degeneration in SMA is a P53-dependant
process. P53 has been identiﬁed in synaptosomes of cor-
tical neurons26. Synaptosomes from P53 knockout mice
displayed reduced levels of reactive oxygen species and
preserved mitochondrial membrane potential following
exposure to the topoisomerase-II inhibitor etoposide26.
Furthermore, mitochondria in isolated synaptosomes
from P53 knockout mice showed greater resistance to
excitotoxic or oxidative insults, and inhibition of P53
decreased synapse loss in hippocampal neuron cultures
following treatment with etoposide. This clearly shows
that P53 can have a local role in mediating synapse loss
and mitochondrial dysfunction. An increase in P53
phosphorylation has also been observed following trophic
withdrawal, a stimulus known to result in axon pruning32.
How then, might P53 mediate the removal of axonal and
synaptic compartments of the cell? A signiﬁcant body of
work has implicated pro-apoptotic proteins and pathways
in the process of axon degeneration33. Interestingly, this
includes developmental axon pruning, which demon-
strates that the activation of apoptotic cascades can be
compartment speciﬁc and that mediating removal of
axonal and synaptic parts of the neuron allow the motor
neuron to persist. Indeed, it has been suggested that as
P53 has the ability to regulate both pro- and anti-apop-
totic transcripts, it can serve as a key regulator for com-
partmental degeneration in neurons32,34. Further work is
clearly required to identify the molecular effectors of
P53-dependant synaptic degeneration in SMA, and
determine whether P53 is an important mediator of
axonal and synaptic degeneration in other neurodegen-
erative contexts.
Fig. 5 Reducing P53 levels in Smn2B/− mice does not alter the number or size of MNCBs in the ventral horn of the spinal cord at P15. a
Representative images showing MNCBs in the ventral horn of the spinal cord at P15of Smn2B/+; P53+/+ and Smn2B/+; P53−/−mice and Smn2B/−; P53+/+
and Smn2B/−; P53−/− mice. White arrowheads point out MNCBs. The grayscale images shown below each coloured image are the sperate channels
and show, from left to right, ChAT, Nissl and DAPI staining. Scale bar= 40 μm. b The graph (mean ± SEM) shows that when P53 is reduced there is no
signiﬁcant difference in the number of MNCBs in the ventral horn of both Smn2B/+ and Smn2B/− spinal cords at P15. There is a signiﬁcant difference in
the loss of MNCBs in Smn2B/− mice compared to Smn2B/+ mice (by one-way ANOVA; ns > 0.05, ****p < 0.001; n= 3 mice per genotype). c The graph
(mean ± SEM) shows that when P53 is reduced there is no signiﬁcant difference in the area of MNCBs in the ventral horn of both Smn2B/+ and Smn2B/−
spinal cords (by one-way ANOVA; ns > 0.05; n= 3 mice per genotype)
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Fig. 6 (See legend on next page.)
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P53 independent motor neuron loss in SMA
An upregulation of transcripts associated with the
P53 signalling pathway has been consistently observed
in response to reduced Smn levels8,21–24. Due to the
well-established links between P53 and caspase medi-
ated apoptosis, this has led to the suggestion that motor
neurons in SMA are dying by a P53 mediated form of
apoptosis. In this canonical pathway, an increase in cell
stress, brought about by a variety of triggers, causes the
phosphorylation and activation of P53, which in turn act
as a transcription factor for a number of pro-apoptotic
transcripts including Bax, Bak and Pmaip. These factors
cause an increase in the permeability of the mitochon-
drial membrane, resulting in a release of pro-apoptotic
factors, leading to the activation of effector caspases.
This includes caspase 3, which mediates the cleavage of
cellular components and is essential for the chromatin
condensation and DNA fragmentation, all of which are
morphological hallmarks of apoptosis. The data pre-
sented here demonstrate that inhibition of P53 does not
reduce motor neuron loss, suggesting that motor neu-
ron loss in this mouse model is P53 independent.
Although this is in contrast to recent reports showing
P53 inhibition could reduce motor neuron loss in the
Smn−/−; SMN2; SMNΔ7 mouse model of SMA, this
ﬁnding is in agreement with previous work showing
knockout of P53 has no beneﬁcial effect on a mouse
model of SMA9,35. There are also interesting parallels to
work on the SODG93A mouse model of ALS, showing
knockout of P53 has no effect upon motor neuron
loss36, despite the observation that P53 levels are ele-
vated in postmortem tissue, cellular models and mouse
models of ALS16,17,19,37–40. Whilst this could be due to a
degree of redundancy between P53 and related path-
ways, it does demonstrate that motor neurons in SMA
can die by a P53 independent mechanism.
Studies detailing apoptotic motor neurons in SMA are
notably lacking. Although some have reported features
consistent with apoptosis in postmortem and cellular and
animal models, work using immunohistochemical
approaches to label apoptotic revealed no difference
between SMA and control patients in either fetal or
newborn individuals with SMA20,35,41,42. However,
knockout of the pro-apoptotic protein Bax in a mouse
model of SMA did reduce motor neuron loss43. More
work is required to deﬁne whether motor neurons in
SMA are degenerating via a caspase dependant apoptosis,
and investigate P53 independent up-stream regulators of
this process. Identifying this mechanism will be of fun-
damental importance if we are to gain a thorough
understanding of motor unit pathogenesis in SMA.
Materials and methods
Mouse maintenance
Smn2B/2B (originating from the Kothary Laboratory,
Ottawa Hospital Research Institute) mice were crossed
with Smn+/− (Strain: 10921, Jackson Laboratories) to
produce Smn2B/− experimental mice and Smn2B/+ con-
trols. Smn+/− mice were crossed with mice carrying the
P53ﬂ/ﬂ and CAG-Cre alleles (generously donated by Dr
Luke Boulter, Kevin Myant and You-Ying Chou, Uni-
versity of Edinburgh) to obtain Smn+/−; P53ﬂ/ﬂ; CAG-Cre
mice. Smn2B/2B mice were interbred with mice carrying
the P53ﬂ/ﬂ allele to obtain Smn2B/2B; P53ﬂ/ﬂ mice. Smn+/−;
P53ﬂ/ﬂ; CAG-Cre and Smn2B/2B; P53ﬂ/ﬂ mice were
interbred to produce Smn2B/+; P53ﬂ/ﬂ; CAG-Cre, Smn2B/+;
P53ﬂ/ﬂ, Smn2B/−; P53ﬂ/ﬂ; CAG-Cre and Smn2B/−; P53ﬂ/ﬂ
mice. All genotyping was performed using standard PCR
protocols. Homozygosity for the P53ﬂ allele was con-
ﬁrmed using q-PCR. All mice were maintained at the
University of Edinburgh animal facilities on a C57Bl6
background. Mice aged over P10 were sacriﬁced by
overdose of inhalation anaesthetic or a rising CO2 and
death was conﬁrmed by exsanguination from the carotid
artery. Mice under P10 were decapitated under terminal
anaesthesia and death was conﬁrmed by exsanguination
from the carotid artery. Endstage of disease was deﬁned
by over 10% loss of weight over a period of 48 h. Since no
phenotypic differences have been noted between male and
female mice, experiments were not controlled for gender.
All experiments were performed in accordance with the
UK Home Ofﬁce.
(see ﬁgure on previous page)
Fig. 6 Reduction in P53 reduces NMJ loss but does not affect other morphological signs of degeneration. a Representative images showing
NMJs from the TVA of Smn2B/−; P53+/+ and Smn2B/−; P53−/− mice. Note that the white arrowheads point out vacant endplates. Scale bar= 40 μm. b
The graph (mean ± SEM) shows that a reduction in P53 decreases denervation in the TVA muscle, with Smn2B/−; P53−/− mice showing a signiﬁcant
increase in the percentage of fully occupied endplates compared to Smn2B/−; P53+/+ mice (by Mann–Whitney-U test; **p < 0.01; n= 6 muscles per
genotype). c In addition, this graph (mean ± SEM) shows a signiﬁcant decrease in the percentage of vacant endplates in Smn2B/−; P53−/− mice
compared to Smn2B/−; P53+/+ mice (by Mann–Whitney-U test; *p < 0.05; n= 6 muscles per genotype). d The graph (mean ± SEM) shows that there is
no signiﬁcant difference in the level of pre-synaptic swelling in the TVA of Smn2B/−; P53+/+ and Smn2B/−; P53−/−mice (by Mann–Whitney-U test; ns >
0.05; n= 6 muscles per genotype). e The graph (mean ± SEM) shows that there is no signiﬁcant difference in the maturity of endplates in the TVA of
Smn2B/−; P53+/+ and Smn2B/−; P53−/− mice (by Mann–Whitney-U test; ns > 0.05; n= 6 muscles per genotype). f The graph (mean ± SEM) shows that
there is a small but signiﬁcant decrease in the area of endplates in the TVA of Smn2B/−; P53+/+ and Smn2B/−; P53−/− mice (by Unpaired T-test; *p <
0.05; n= 6 muscles per genotype)
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Tamoxifen
Tamoxifen (Sigma-Aldrich) was dissolved in corn oil to
a concentration of 20 mg/ml. Tamoxifen solution was
administered to litters of mice at P4 and P5 using oral
gavage at a dose of 75 mg/kg.
Phenotypic analysis
The ‘time to right’ test was carried out on mice at P8
and P10. Mice were placed on their back and the time it
took for them to right themselves (turn to be on all four
paws) was noted, with a maximum of 30 sec and an
average of three attempts.
The ‘turn around test’ was used on mice daily aged over
P12. This test involved placing mice, head down on a
gridded cage top that was at a 45o angle. The time it took
for mice to turn 180o to face up was noted, with a max-
imum of 30 sec and an average of three attempts.
Neuromuscular junction labelling and quantiﬁcation
Muscles were immediately dissected from recently
sacriﬁced mice and ﬁxed in 4% Paraformaldehyde (PFA;
Electron Microscopy Science) in PBS for 15min. Post-
synaptic AChRs were labelled with α-bungarotoxin (BTX,
1:250; tetramethylrhodimine conjugate, Life Technolo-
gies) for 2 h. Muscles were permeabilised in 2% Triton X-
100 in PBS for 30min, then blocked in 4% bovine serum
albumin (BSA)/1% Triton X-100 in PBS for 30min before
incubation overnight in primary antibodies [Neuroﬁla-
ment, 1:50 (NF; 2H3)—Developmental Studies Hybri-
doma Bank; synaptic vesicle protein 2, 1:100 (SV2)—
Developmental Studies Hybridoma Bank] and visualised
with secondary antibodies [AlexaFluor-488 rabbit anti-
mouse at 1:250, Jackson]. Muscles were then whole-
mounted in Mowiol (Sigma).
All images were quantiﬁed using a Leica inverted
ﬂuorescent microscope using single and dual wavelength
ﬁlter sets allowing separate and simulations visualisation
of red and green channels. The percentage of fully occu-
pied endplates was determined by classifying each end-
plate in a given ﬁeld of view either fully occupied (pre-
synaptic terminal (SV2 and NF) completely overlies
endplate (BTX)), partially occupied (pre-synaptic terminal
only partially covers endplate (BTX)), or vacant (no pre-
synaptic label overlies endplate). For pre-synaptic swel-
ling, all NMJs were classiﬁed as having no swelling, mild
(evidence of some axonal swelling and/or pre-synaptic
swelling that does not obscure the endplate), moderate
(evidence of clear axonal swelling and signiﬁcant pre-
synaptic swelling that is beginning to obscure the end-
plate) or severe (signiﬁcant and obvious swelling along the
length of the axon and severe swelling around the pre-
synaptic terminal, which obscures the endplate). Endplate
size was quantiﬁed using ImageJ software. Endplate
maturation was quantiﬁed using a stage 1–4 categorisa-
tion, where stage 4 endplates are immature and have a
plaque-like appearance, stage 3 endplates are developing
from a plaque-like structure with folds visible on the
plaque, stage 2 endplates are developing into a pretzel-like
structure with folds and perforations visible and stage 1
endplates have a mature pretzel-like structure. At least
three ﬁelds of view were analysed per muscle totalling >80
endplates per muscle. All Quantiﬁcation was performed
with researcher blind to genotype of material. All example
images are z-stack projections and were obtained using a
Nikon confocal microscope at ×40 magniﬁcation and
images had pixel size of 1024 × 1024.
Motor neuron immuno-ﬂuorescence and quantiﬁcation
Spinal cords were removed from recently sacriﬁced
mice and ﬁxed in 4% PFA (Electron Microscopy Science)
for 4 h. They were immersed in 30% sucrose for 48 h prior
to embedding in 50% OCT; 15% Sucrose in PBS mixture.
For temporal analysis of Smn2B/− mice, the ventral horn
of thoracic (T1-T12) spinal cords were sectioned long-
itudinally at 10 µM and alternate sections were subjected
to Nissl/ChAT labelling. For analysis of P53ﬂ/ﬂ mice,
thoracic (T4-T8) spinal cords were sectioned coronally at
10 µM and every tenth section was subjected to Nissl/
ChAT labelling.
Sections were washed in PBS, permeabilised in 0.3%
Triton X-100 in PBS for 30min and blocked in 0.1%
Power Block (100× , Biogenex Laboratories, HK085–5K)
in PBS for 10min. Sections were incubated in ChAT
(Goat anti-choline acetyl-transferase; Merck Millipore;
1:100) primary antibody in 0.3% Triton X-100; 1% Bovine
Serum Albumin (BSA) in PBS at 4 °C, for three nights.
Secondary antibody (AlexaFluor 555 Donkey anti-Goat;
Life Technologies; 1:250) was applied for 2 h at a dilution
of 1:250 at room temperature. Sections were then stained
with DAPI (Life Technologies; 1:1000) and ﬂuorescent
Nissl stain (NeuroTrace; Life Technologies: 1:100). Sec-
tions were mounted in Mowiol (Sigma).
For quantiﬁcation of motor neuron number, the num-
ber of ChAT positive cells with a visible nucleolus were
quantiﬁed in each section. For Fig. 2, this was done on
longitudinal section, quantifying every second section. For
Fig. 5, this was done on coronal section, for every 30th
section. For motor neuron cell body area, images were
captured on a standard ﬂuorescent microscope (Leica
DM8) and the perimeter of each cell was traced using
ImageJ software. All data was assembled in Microsoft
Excel and analysed using GraphPad Prism.
qRT-PCR
RNA was extracted using a micro RNeasy Kit (Qiagen)
and 1 µg of RNA was used to perform reverse
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transcriptase using the RT2 First Strand Kit (Qiagen).
SYBR gene based Q-RT-PCR was performed using pre-
optimised primers purchased from Qiagen. Ampliﬁcation
was performed using KAPA SYBR fast universal PCR
mastermix as per manufacturer's instructions on a BioRad
CFX connect real-time PCR detection system. Relative
gene expression was calculated using the 2−ΔΔcT for-
mula44. Relative levels are expressed normalised to Actin
(F: CCGTCAGGCAGCTCATAGCTCTTC; R: CTGAAC
CCTAAGGCCAACCGT), GusB (F: GGCTGGTGACC-
TACTGGATTT; R: TTGGCACTGGGAACCTGAAGT)
and YWHAZ (F: TTGATCCCCAATGCTTCGC;
R:: CAGCAACCTCGGCCAAGTAA).
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